NASDAQ$SGHT

Sight Sciences Inc · Q4 2024 earnings

Q4 2024 earnings · · After market close · Investor relations

Briefing

Sight Sciences reported Q4 2024 revenue of $19.1M.

For Q4 2024, Sight Sciences reported Revenue was $19.1M. Management discusses segment trends, liquidity, and outlook in the quarterly filing.

  • Revenue $19.1M for Q4 2024.
  • MD&A highlights operating priorities, liquidity, and sector risks.
  • MD&A highlights operating priorities, liquidity, and sector risks.

Headline financials

Total Revenue

$19.1M

Previous: $18.8M+1.9%
EPS (adj)

-$0.23

Previous: -$0.22-4.5%
Total Gross Margin

86.8%

Previous: 85.2%+1.9%
Operating Expenses

$28.5M

No prior period
Adjusted Operating Expenses

$24.4M

No prior period
Glaucoma Gross Margin

87.4%

No prior period
Dry Eye Gross Margin

51.0%

No prior period
Glaucoma Active Customers

1.1K

Previous: 1.1K+7.0%
Dry Eye Units Sold

1.1K

Previous: 5.2K-78.4%
Dry Eye Active Customers

83

Previous: 327-74.6%
Capital Expenditures

-$137K

Previous: $264K-151.9%
Net Income

-$11.8M

Previous: -$10.7M-10.8%
Operating Income

-$11.9M

Previous: -$11.1M-7.4%
Gross Profit

$16.6M

Previous: $16M+3.7%
R&D Expense

$4.29M

Previous: $3.43M+25.3%

Revenue & EPS history

Sight Sciences · Revenue · Quarterly

$19.1M

Q4 2024+1.9%vs Q4 2023
Beat estimate in 10 of 15 quarters(67%)
ActualEstimate

Revenue by segment

Sight Sciences · $20M total across 2 segments · Q3 2023

  • Interventional Glaucoma
    $18.4M+7.6%
  • Interventional Dry Eye
    $1.6M+0.0%

Forward guidance

Outlook emphasizes clinical milestones, cash runway, and R&D spend.

Tailwinds

  • Pipeline progress and partnership optionality.
  • Balance-sheet flexibility where noted.

Headwinds

  • Operating losses until commercialization.
  • Trial, regulatory, and financing risks.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 18 quarterly earnings reports · overlaid with Q4 2024

Historical avgQ4 2024

+3.0%

Avg return

Earnings day

+4.0%

Avg return

5 days after

+5.0%

Avg return

30 days after

53%

10 / 19 earnings

Positive

+60.9%

Q3 2022

Best reaction

-26.9%

Q4 2025

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-0.7%+22.6%+2.5%
Q4 2025-26.9%-25.9%-34.9%
Q3 2025+16.0%+54.4%+61.0%
Q1 2025+1.3%+8.3%+38.6%
Q4 2024+2.9%+15.3%-5.0%
Q3 2024-17.1%-17.1%-24.1%
Q2 2024-18.9%-29.4%-13.0%
Q1 2024+6.6%+1.1%+17.4%
Q4 2023+6.8%-4.4%+21.4%
Q3 2023+19.8%+2.0%+54.1%
Q2 2023+11.0%+4.1%-16.0%
Q1 2023-0.4%+0.6%-25.1%
Q4 2022+4.9%-2.3%-5.8%
Q3 2022+60.9%+50.4%+72.9%
Q2 2022-3.9%-16.1%-26.2%
Q1 2022+11.2%+23.9%+59.2%
Q4 2021-10.1%-6.1%-45.5%
Q3 2021-2.4%-5.8%-20.6%
Q2 2021-4.7%+0.1%-15.9%
Q4 2020
Q3 2020
Q2 2020
Q1 2020

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro